January 21, 2020 10:37 AM EST

AstraZeneca scores orphan status for PD-L1/CTLA-4 combo; EMA OKs Novartis' MS drug Mayzent

ENDPOINTS

→ AstraZeneca gained an orphan drug designation for its combination of Imfinzi and the CTLA-4 drug tremelimumab for hepatocellular carcinoma …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca scores orphan status for PD-L1/CTLA-4 combo; EMA OKs Novartis' MS drug Mayzent

ENDPOINTS

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

As­traZeneca scores or­phan sta­tus for PD-L1/CT­LA-4 com­bo; EMA OKs No­var­tis' MS drug Mayzent

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

AstraZeneca scores orphan status for PD-L1/CTLA-4 combo; EMA OKs Novartis' MS drug Mayzent